SEC Form 4 · accession 0000899243-16-031634
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tricia Borga Suvari
Officer — Chief Legal Officer
Period of report
Oct 11, 2016
Accepted (ET)
Oct 12, 2016 · 9:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $18.25 | Oct 11, 2016 | A | 100,000 | A | — | Oct 10, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest and become exercisable on October 11, 2017, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.